Additional partnership in medical technology: Bosch and R-Biopharm to strengthen Vivalytic analysis platform
Plans to use innovative Bosch BioMEMS technology in PCR tests for multiresistant bacteria
- Bosch and R-Biopharm are jointly investing 150 million euros in the development of new PCR tests and in marketing.
- PCR test for multiresistant gram-negative (MRGN) bacteria to be developed using novel BioMEMS technology.
- BioMEMS chips permit simultaneous testing of up to 250 genetic characteristics – in some cases, in less than 15 minutes.
Darmstadt, Gerlingen, and Waiblingen, Germany – The market for medical technology is innovative, dynamic, and growing. Bosch sees medical technology as a strategic growth field and intends to expand its Bosch Healthcare Solutions subsidiary, based in Waiblingen. Bosch has now entered into a new partnership with the German diagnostics solutions company R-Biopharm. This partnership will be focused on Bosch’s universal, fully automated Vivalytic molecular diagnostic analysis platform. The two companies will invest a total of 150 million euros by the end of the decade. Within their strategic development and distribution partnership, the partners intend to develop new in vitro diagnostic tests for the Vivalytic platform – including a PCR test for multiresistant bacteria based on the innovative Bosch BioMEMS technology. They are also looking to strengthen their marketing operations.
“We are expanding in medical technology, a market we have defined as a strategic growth field. The fact that we can apply our many years of expertise and experience in the research and development of microchips, molecular diagnostics, and miniaturization, as well as our manufacturing know-how, makes this an attractive prospect for us,” says Stefan Hartung, chairman of the Bosch board of management. “In medical technology, partnership models are a useful way of shortening product cycles and opening up distribution channels in this dynamic, innovative market,” he adds. Point-of-care molecular diagnostics is expected to become a market worth billions. Bosch Healthcare Solutions and
R-Biopharm aim to achieve sales in the medium nine-figure range by 2030.
The R-Biopharm Group, based in Darmstadt, Germany, has many years of expertise in clinical and food diagnostics. In addition, the company has well-established sales channels worldwide and knowledge of the relevant markets. “Our partnership with Bosch Healthcare Solutions marks a significant milestone in the implementation of the R-Biopharm Group’s growth strategy in the field of clinical diagnostics,” says Dr. Frank Apostel, Chief Operating Officer Clinical Diagnostics and Nutrition Care at R-Biopharm. “Together, we will work toward the goal of offering excellent products and solutions that can play a major part in combating diseases and developing medicines,” he adds.
Partnership goals: develop new PCR tests and strengthen sales
One development goal within the ten-year partnership is a test for multiresistant gram-negative (MRGN) bacteria, which is to be implemented using Bosch’s innovative, novel BioMEMS technology. The healthcare system faces the challenge of coping with an increasing number of diseases caused by multiresistant bacteria: in 2019, antimicrobial resistance had a hand in 4.95 million deaths worldwide, and each year, 670,000 infections caused by antibiotic-resistant bacteria occur in Europe. In recent years, these bacteria have become a problem in hospitals – which administer particularly large quantities of antibiotics in the course of treating patients. In addition to the health risks, the financial burden of hygiene and quarantine measures in the healthcare sector should not be underestimated.
Vivalytic: even faster and more efficient with Bosch BioMEMS technology
As compact as a desktop computer tower, the universal, fully automatic Vivalytic Analyser is a platform for which various manufacturers can quickly and easily adapt and implement tests. The test cartridges already contain all the necessary reagents. “You could say we’ve shrunk a laboratory down to the size of a smartphone,” says Marc Meier, president of Bosch Healthcare Solutions. “BioMEMS technology makes our Vivalytic platform even faster and more efficient, since this high-performance silicon chip, developed and manufactured by Bosch, enables fully automatic, simultaneous testing of up to 250 genetic characteristics such as pathogens in a single test cartridge, in some cases in less than 15 minutes,” he adds. “This marks the entry of Bosch and its partners into nanofluidics, which processes very small quantities of liquids in the nanoliter range.” This further miniaturization underscores the advantages of the Vivalytic platform: its compact size enables fast and targeted diagnostics directly at the point of sample collection – either at the doctor’s office or in the hospital – without the frequently time-consuming detour via a central laboratory. Medically trained specialists can carry out the PCR tests without special laboratory training.
The two companies want to develop further PCR tests to detect tuberculosis and determine any drug resistance. A few days ago, Bosch announced its first partnership with the Northern Irish medical technology company Randox Laboratories Ltd. By the end of the decade, Bosch and its two partners will have invested some 300 million euros in the further development of the Vivalytic analysis platform.
Press photos and infographics are available on the Bosch Media Service at www.bosch-press.com.
Bosch contact:
Dörthe Warnk
Phone: +49 711 811-55508
E-mail: doerthe.warnk@bosch.com
R-Biopharm contact:
Yvonne Kress
Phone: +49 6151 8102-4319
E-mail: Y.Kress@r-biopharm.de
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
QUERSUS AND AUDI COMBINE UNIQUE MOTORSPORT DESIGN WITH FUTURISTIC ERGONOMIC CHAIRS30.8.2024 13:23:14 CEST | Press release
August 30, 2024 – Quersus, one of the leading European ergonomic chair manufacturers, proudly announces an exceptional collaboration with Audi, the renowned German premium car manufacturer. Together, they present two exclusive Quersus models under the Audi license: the Quersus VAOS Audi RS Q e-tron and the Quersus ICOS Audi. These chairs embody the essence of innovation and design, combining superior comfort with cutting-edge automotive aesthetics. Cutting-Edge Designs inspired by Audi The Quersus VAOS Audi Gaming Chair: Inspired by the design of the Audi RS Q e-tron, victorious in the 2024 Dakar Rally, this gaming chair reflects the spirit of competition and advanced technology. Its bold lines echo the dynamic design of Audi's off-road prototype vehicle. The Quersus ICOS Audi Office Chair: Inspired by the design of the Audi single-seater study, this ergonomic hybrid office chair with a sporty curve embodies the innovation and pursuit of performance of Audi vehicles. Its modern design,
enomyc supports M&A Deal: Multinational AI Alliance Formed to Combat Online Hate27.8.2024 16:43:23 CEST | Press release
Paris / Hamburg, August 27th 2024 – With the acquisition of the Spanish AI specialist Insikt AI by the British company Logically, the M&A experts at the consulting firm enomyc have successfully completed another international transaction. enomyc's Paris office, which led the deal with support from German colleagues, was exclusively commissioned by Insikt AI to find a strategic partner. The acquisition creates a new multinational player in the fight against online hate.
Green expands its data center capacity27.8.2024 08:29:55 CEST | Pressmeddelande
Leading Swiss data center provider Green is building another high-performance data center on the Metro-Campus Zurich West. The demand for computing power has risen sharply.
Cool Concept for International Logistics20.8.2024 13:15:00 CEST | Press release
Mannheim/Germany-based eutecma GmbH with Second Location in the USA
TÜV SÜD förvärvar Carspect Group14.8.2024 13:00:00 CEST | Pressmeddelande
München/Stockholm. TÜV SÜD tillkännager förvärvet av svenska Carspect Group Holding AB. Koncernen, med säte i Stockholm, utför kontrollbesiktningar och andra fordonsrelaterade tjänster på över 150 besiktningsstationer i Sverige, Lettland och Estland.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom